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Abstract
Background: A growing number of observational and epidemiological studies have suggested that
mental illness, in particular mood disorders, is associated with reduced dietary intake and/or
cellular abundance of omega-3 polyunsaturated fatty acids (PUFA). This has prompted researchers
to test the efficacy of omega-3 PUFA in a range of different psychiatric disorders. We have critically
reviewed the double blind placebo controlled clinical trials published prior to April 2007 to
determine whether omega-3 PUFA are likely to be efficacious in these disorders.
Results: Most trials involved a small number of participants but were largely well designed.
Omega-3 PUFA were well tolerated by both children and adults with mild gastrointestinal effects
being the only consistently reported adverse event. For schizophrenia and borderline personality
disorder we found little evidence of a robust clinically relevant effect. In the case of attention deficit
hyperactivity disorder and related disorders, most trials showed at most small benefits over
placebo. A limited meta-analysis of these trials suggested that benefits of omega-3 PUFA
supplementation may be greater in a classroom setting than at home. Some evidence indicates that
omega-3 PUFA may reduce symptoms of anxiety although the data is preliminary and inconclusive.
The most convincing evidence for beneficial effects of omega-3 PUFA is to be found in mood
disorders. A meta-analysis of trials involving patients with major depressive disorder and bipolar
disorder provided evidence that omega-3 PUFA supplementation reduces symptoms of depression.
Furthermore, meta-regression analysis suggests that supplementation with eicosapentaenoic acid
may be more beneficial in mood disorders than with docosahexaenoic acid, although several
confounding factors prevented a definitive conclusion being made regarding which species of
omega-3 PUFA is most beneficial. The mechanisms underlying the apparent efficacy of omega-3
PUFA in mood disorders compared to schizophrenia are discussed as is a rational for the possibly
greater efficacy of EPA compared to DHA. 
Conclusion: While it is not currently possible to recommend omega-3 PUFA as either a mono-
or adjunctive-therapy in any mental illness, the available evidence is strong enough to justify
continued study, especially with regard to attentional, anxiety and mood disorders.
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Background
Omega-3 fatty acids are a type of polyunsaturated fatty
acid (PUFA). PUFA are so-called because they are not 'sat-
urated' with hydrogen atoms at multiple (poly) locations
within the molecule and, as a result, contain two or more
carbon-carbon double bonds. They form one of the three
main classes of fatty acids, the others being saturated, in
which all available hydrogen atom positions are filled,
and monounsaturated, in which a single carbon-carbon
double bond exists. PUFA are subdivided into the omega-
3 (n-3) series (the first double bond is 3 carbons from the
end (omega) carbon atom of the molecule) that are syn-
thetically derived from linoleic acid (LA), and the omega-
6 (n-6) series which are derived from alpha-linolenic acid
(ALA), both 18 carbon atom containing fatty acids. LA
and ALA are termed essential fatty acids because mamma-
lian cells are unable to synthesize these fatty acids from
simpler precursors. LA can be converted sequentially via a
biosynthetic pathway into other omega-6 fatty acids, the
18 carbon gamma linolenic acid (GLA), and the 20 car-
bon arachidonic (AA) and dihomogammalinolenic acids
(DGLA). Similarly, ALA is converted into longer chain
omega-3 fatty acids such as 20 carbon eicosapentaeoic
acid (EPA) and 22 carbon docosahexaenoic acid (DHA).
Increasing evidence indicates, however, that although LA
and ALA can be converted into their longer chain length
metabolites, the rate of conversion in humans is very
slow, resulting in an estimated 2 to 10% of ALA being con-
verted to DHA or EPA [1,2]. This suggests that a major
source of the longer chain polyunsaturated fatty acid spe-
cies such as EPA and DHA is likely to be dietary. Such a
view is supported by data that supplementation with fish
oils can markedly elevate the cellular levels of both these
omega-3 PUFA [3].
Omega-3 PUFA are of particular interest from a nutri-
tional standpoint since the intake of these fatty acid is
considered to be low in Western diets [4]. They have long
been investigated for their cardioprotective and anti-
inflammatory roles, which has lead to their increased use
as dietary supplements [5]. A new application for omega-
3 fatty acids has emerged recently, the treatment of certain
forms of mental illness. Such a use is biologically plausi-
ble given that omega-3 fatty acids, in particular DHA, are
abundant in the brain and are involved in, or modulate,
the mechanism by which brain neurons communicate [6].
They have been shown to alter the functioning of neural
systems utilising dopamine and serotonin, both of which
are thought to play an important role in mental illness
and are major targets of psychoactive medications [6,7].
Furthermore, animal models of mental illness have sug-
gested that omega-3 fatty acids can affect brain processes
such as those that control mood and anxiety [8].
Methods
This review considers the findings of the clinical trials that
form the basis of these developments and whether or not
they offer convincing support for the use of omega-3
PUFA as a treatment for mental illness. To accomplish this
we utilized PubMed and PsycINFO to identify placebo-
controlled clinical trials of omega-3 fatty acids in psychi-
atric disorders. The strategy employed was to search for
articles which contained search terms from list 1 (schizo-
phrenia, psychosis, delusion, bipolar, mania, depression,
mood, personality, anxiety, obsession, attention, hyperac-
tivity, autism, retardation, somatoform, anorexia,
bulimia, cognitive) and from list 2 (omega-3, n-3 alpha
linoleic, eicosapentaenoic, docosahexaenoic, EPA, DHA,
ALA). We also searched using Pubmed for omega-3, n-3,
alpha linoleic, eicosapentaenoic, docosahexaenoic, EPA,
DHA, or ALA limited by clinical trial. We reviewed these
trials with respect to their findings, statistical analysis and
overall trial quality.
For all trials we assessed the evidence that trial partici-
pants who had received omega-3 PUFA had improved
psychopathology compared to those who received pla-
cebo treatment. This was accomplished by extracting or
calculating the change-from-baseline scores for the appro-
priate clinical rating scale for each disorder, and then cal-
culating the mean difference in change-from-baseline
scores between the placebo and omega-3 PUFA groups. A
standardized or unstandardized difference value of zero
indicates that there was no difference in the effect upon
psychopathology between the two groups. For the atten-
tion deficit hyperactivity disorder (ADHD) and depres-
sion trials we constructed Forest plots of the standardized
mean differences in change-from-baseline scores for the
comparable trials. For the depression trials, we calculated
an inverse-variance-weighted overall estimate of effect
using the random effects method [9] as well as conducting
a meta-regression to identify sources of heterogeneity
between the trials [9]. We conducted all analyses using
STATA version 9.2 (Stata Corp, College Station, TX).
The quality of the trial design was assessed using the Jadad
scoring system [10] which takes into account whether the
trial was double blind, randomized using an appropriate
method, whether withdrawals from the trial were
described and whether an appropriate placebo was used.
A higher score indicates a higher apparent design quality.
The trials considered varied in quality, utilised a variety of
clinical outcome measures, and used a variety of fatty acid
formulations including DHA or EPA rich fish oils, as well
as a semi-purified (96%) ethyl-EPA ester. A further aim of
this review was therefore to assess the evidence of whether
EPA or DHA is more efficacious in any form on mental ill-
ness. Notably, all trials utilised the long chain (20 carbonLipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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atoms or greater) omega-3 PUFA rather than the 18 car-
bon atom ALA.
Results
The effect of omega-3 PUFA upon psychopathology was
investigated in a range of psychiatric disorders that we will
consider by general disease class.
Attention deficit hyperactivity disorder and related 
disorders
Attention deficit/hyperactivity disorder (ADHD) is a com-
mon disorder of school age children (although adults can
also be affected). Estimates vary but the prevalence of
ADHD is thought to be in the range of 2 – 7% of children
[11]. As the name suggest ADHD comprises hyperactivity
and a range of attentional deficits including problems lis-
tening, paying attention and finishing tasks, as well as
interrupting others [12]. The illness is also associated with
social withdrawal, shyness and anxiety and around one
quarter of children with ADHD may also show learning
difficulties including problems with reading and writing
[13]. Such behavioural problems can affect academic
attainment as well as relationships with family and peers.
Over 80% of children with ADHD in the US are treated
with stimulants such as methylphenidate (Ritalin). While
efficacious in some patients, these medications have sig-
nificant side effects including decreased appetite, insom-
nia, impaired growth and irritability [13]. Although the
aetiology of ADHD is unclear, one suggested contributory
factor is diet including the abnormal intake and abun-
dance of various types of PUFA [14,15]. Reduced PUFA
levels have been reported in both plasma and erythrocyte
membranes of children with ADHD [16-19], while a pre-
liminary study suggests that omega-3 fatty acid break-
down occurring consequent to oxidative stress is increased
[20]. Such findings have led to the hypothesis that lack of
sufficient amounts of specific fatty acids affects brain func-
tion in such a way as to cause or worsen the symptoms of
ADHD [14]. Early studies examining the effects of essen-
tial fatty acid supplementation focused exclusively on
omega-6 fatty acids. In double-blind placebo-controlled
trials of mixtures of gamma linoleic acid and LA in chil-
dren with ADHD both Aman and colleagues [21] and
Arnold and colleagues [22] reported no significant
improvement in symptoms. Despite such negative results,
the encouraging data emanating from early trials of
omega-3 fatty acids in depression and schizophrenia
(described later in this review) prompted investigation of
these fatty acids in ADHD and related disorders.
Interest in the interaction between diet and attentional
disorders is currently high with Joshi and colleagues [23]
reporting decreased hyperactivity in children with ADHD
receiving flax oil (an oil rich in the 18 carbon omega-3
fatty acid ALA) in a non-placebo-controlled trial. Further-
more, Fontani and colleagues [24] reporting that omega-
3 fatty acid supplementation enhances measures of atten-
tion in healthy adults. In addition, five double-blind pla-
cebo-controlled trials have been carried out that examine
how omega-3 PUFA supplementation affects attention
and hyperactivity (Table 1). The trials used a variety of
outcome measures. We have summarized a small subset
of the results with a focus on two aspects of ADHD, atten-
tion and hyperactivity (Table 1). The first ADHD study
was conducted by Voigt and colleagues [25]. These
researchers tested the effect of 345 mg/day DHA for 4
months upon 63 children with the disorder. Although
blood DHA levels were increased in the active treatment
group, no significant difference in symptoms was
observed compared to placebo and assessed using the
Child Behaviour Checklist [26] and the Conners' rating
scale [27] (Conner's scale data is not shown in the report).
No significant benefit of a DHA/EPA mixture compared to
placebo was also reported by Hirayama and colleagues
[28]. Rather than being in capsule form, the DHA supple-
mentation was administered through DHA fortification of
food stuffs. As such, the daily dose can only be estimated
but was approximately 100 mg EPA and 500 mg DHA/
day. The authors report that the number of different
symptoms present which comprise an ADHD diagnosis
(as described in the Diagnostic and Statistical Manual for
Mental Disorders Version IV abbreviated to DSM-IV [12]),
was not changed compared to placebo by omega-3 PUFA
administration. It is important to note, however, that the
authors did not assess the severity of symptoms, merely
their presence. Such a measure may not possess sufficient
sensitivity to detect smaller improvements in the condi-
tion however.
The three other trials differed from the others in that they
did not utilize children with formally diagnosed ADHD
but rather ADHD-related symptoms, as determined using
one or more rating scales. As such the subject groups are
likely to be more heterogeneous than found in the trials
conducted by Voigt and colleagues [25] and by Hirayama
and colleagues [28], and likely contain participants who
would not meet the DSM-IV criteria for clinical ADHD.
Richardson and Puri [29] tested the effects of a supple-
ment containing a mixture of omega-3 and omega-6 fatty
acids in children with learning difficulties (mainly dys-
lexia) who also exhibited ADHD-like features assessed
using the Conner's Teacher Rating Scale. Since the Con-
ner's scale scores are influenced both age and gender,
scores are routinely transformed using standard popula-
tion values which convert the raw scores into standardised
t-scores with mean = 50 and standard deviation of 10. A
score greater than two standard deviations from the mean
(> 70) correlates well with a clinical diagnosis of ADHD
[27]. It is notable that the participants in the RichardsonLipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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and Puri trial [29] have a mean t-score of less than 70,
indicating that most of the participants likely would not
meet the criteria for clinical ADHD. In the trial, subjects
were treated with placebo or 186 mg EPA, 480 mg DHA,
96 mg GLA, 864 mg LA and 42 mg AA/day for 12 weeks.
It is unclear why the authors chose to include the omega-
6 PUFA GLA in the formulation given earlier negative
findings [21,22], however, as noted below, the inclusion
of AA and GLA, a precursor of AA, may be beneficial. The
authors report statistically significant improvements upon
a range of ADHD-like symptoms assessed using the Con-
ner's scale including psychosomatic symptoms and inat-
tention, with cognitive problems and anxiety approaching
statistical significance. Examination of the difference
between placebo and omega-3 PUFA groups indicates,
however, that the beneficial effect of the omega-3 PUFA
treatment was, at most, modest (Table 1). The small
number of study participants in this trial is also a signifi-
cant weakness. A comparable study conducted by Stevens
and colleagues [30] examined fatty acid supplementation
in children with ADHD-related symptoms, such as inat-
tention, hyperactivity, and other disruptive behaviours.
Subjects received either placebo or 480 mg DHA, 80 mg
EPA, 40 mg AA and 96 mg GLA/day for 4 months. No sta-
tistically significant difference between placebo and active
groups was observed for any rating scale when those who
completed the trial were compared (Table 1). Using an
intent-to-treat analysis did however indicate a significant
benefit of fatty acids upon attention assessed by teachers,
and conduct assessed by parents using the Disruptive
Behaviours Scale [31]. An intent-to-treat analysis is con-
sidered more valid since it includes participants who with-
drew from the trial (who are likely to be more be severely
ill) by carrying forward their baseline score (intake score)
to the end of the trial even though they have not partici-
pated fully, or at all, in the study treatment protocol.
Notably, the authors also report that by the end of the trial
a significantly greater proportion of children had moved
out of the clinically significant range for oppositional/
defiant behaviour than in the treatment group. While
these improvements are interesting, the magnitude of the
effects described are relatively small and the trial, like that
by Richardson and Puri [29], is at best suggestive of a
small effect upon attentional deficit and/or hyperactivity.
A further trial [32] used a substantially larger sample size
to investigate the effects of mixed omega-3 and omega-6
supplementation in 117 children with Developmental
Coordination Disorder (DCD) [33]. DCD is characterised
by specific impairments of motor function and shows
Table 1: Double blind placebo-controlled trials of omega-3 fatty acids upon attention and hyperactivity in disorders diagnosed in 
childhood.
Ref Jadad 
score
Disorder Meds Age Gen Omega-3 fatty 
acid
Prep 
type
Duration N Outcomemeasure Average 
baseline 
score
Δ Statistical 
significance 
vs. placebo
25 4 ADHD 100% 9 22% 345 mg/day EPA Crude 
Mixture
4 months 54 CBC-Attention 66 +0.4 No
28 5 ADHD 15% 9 20% 100 mg/day EPA
512 mg/day DHA
Crude 
mixture 
in food
2 months 40 #DSM-Attention 9.5 -1 No
#DSM-Hyperactivity 2 0 No
29 5 LD NS 10 20% 186 mg/day EPA
480 mg/day DHA2
Crude 
mixture
12 weeks 29 CPRS DSM-Attention 63 -4.6 Yes
CPRS DSM-
Hyperactivity
67 -1.0 No
30 3 'ADHD-like' 79% 10 12% 80 mg/day EPA
480 mg/day DHA1
Crude 
mixture
4 months 47 PDBDS-Attention 22 +0.2 No
PDBDS-Hyperactivity 22 -0.6 No
32 5 DCD 0% 9 33% 558 mg/day EPA
174 mg/day DHA3
Crude 
mixture
12 weeks 117 CPRS DSM-Attention 65 -3.5 Yes4
CPRS DSM-
Hyperactivity
61 -3.8 Yes4
Spelling age (months) 94 +5.4 Yes
Reading age (months) 97 +6.2 Yes
34 4 Autism 0% 10 18% 840 mg/day EPA
700 mg/day DHA
Crude 
mixture
6 weeks 13 ABC-Hyperactivity 29 -7.0 No
ADHD, LD and DCD are Attention Deficit Hyperactivity Disorder, Learning Difficulties and Developmental Coordination Disorder respectively. Δ refers to the difference 
between the change from baseline values for placebo and treatment groups (change from baseline symptom scores for the omega-3 fatty acid group minus change from 
baseline scores for the placebo group). Trial quality was assessed using Jadad design quality scores which can range from 0 to 5 with 5 being best. Outcome measures are CBC 
– Attention: Child Behaviour Checklist – Attention Subscale; PDBDS – Attention/Hyperactivity: Attention or Hyperactivity Subscale of Parents Disruptive Behaviour Disorder 
Scale, #DSM – Attention/Hyperactivity: Number of DSM ADHD Attention or Hyperactivity symptoms present, CPRS DSM – Attention/Hyperactivity: DSM Attention/
Hyperactivity Subscale of Conner's Parent Rating Scale Clinical Global Impression, ABC-hyperactivity: Aberrant Behaviours Checklist [34] For reading and spelling age a 
higher age is better hence positive Δ indicates improvement over placebo, for all other scales 0 is best hence negative Δ indicates improvement over placebo. The average 
baseline score is the average of the omega-3 and placebo group scores at the start of the trial. Age refers to the average age in years of the active and placebo groups. Gen 
(gender) refers to the % of female participants in the trial. Meds refers to the percentage of trial participants who were in receipt of conventional medications for attentional 
deficit or hyperactivity. Prep. type describes whether a crude oil mixture or a purified fatty acid was used. Notes: 1–3 Formulation also delivered omega-6 fatty acids: 1 40 mg/
day arachidonic acid and 96 mg/day gamma linoleic acid, 2 96 mg/day gamma linoleic acid, 864 mg/day linoleic acid and 42 mg/day arachidonic acid, 3 60 mg/day linoleic acid. 4 
According to the report it is unclear as to whether statistical significance was calculated using raw scores rather than transformed t-scores. Using the data in the paper the 
statistical significance of the t-score comparison cannot be calculated.Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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substantial overlap with ADHD in terms of difficulties
with organizational skills and attention. Similar to the
author's earlier study [29], the Conner's rating scale values
at entry into are indicative of a study population in which
the majority of participants would likely not meet the cri-
teria for ADHD (quoted in the report as 69% of partici-
pants). Using a double blind, placebo controlled high
quality design (Jadad score = 5) children received either
558 mg EPA, 174 mg DHA and 60 mg GLA/day or placebo
for 12 weeks. The fatty acid supplementation had no sig-
nificant benefit over placebo upon motor function, but,
notably, resulted in statistically significant improvements
in reading age, spelling age and on all except one Con-
ner's'subscale (opposition, cognitive problems, hyperac-
tivity, anxiety, perfectionism, social problems,
impulsivity, and inattention). A concern arises, however,
from the fact that while the p-values for the difference
between omega-3 PUFA and placebo groups reported by
the authors appear impressive, the actual magnitude of
the difference between the groups is much less so. For
example, the change in normalised t-scores for DSM-IV
Attention scales in the PUFA group was better than the
placebo group by only 3.8 points (or 38% of 1 standard
deviation) while the quoted statistical significance is p <
0.00001. Information provided in the report suggests two
possible explanations. Firstly, the authors state [32] that
they used non-parametric tests which, depending on how
the data ranks in each group, could produce such an out-
come although this is unlikely to occur. Secondly, they
state [32] that "group comparisons were therefore per-
formed by using the raw scores obtained by summing
across all items." This suggests that the statistical signifi-
cance quoted is for comparison of raw scores, rather than
the t-scores presented in the paper. Whatever the explana-
tion, it appears that the magnitude of difference between
placebo and PUFA groups is not as striking as is suggested
by the very small p-values. Furthermore, since most of the
participants (69%) did not have clinically significant inat-
tention and/or hyperactivity, it is unclear what the clinical
relevance of the authors observations are, if any. On the
other hand, the authors did find an effect and it will be of
great interest to utilise the same formulation in children
who have clinically significant symptoms as defined using
either the Conner's scale or by psychiatric assessment.
The most recent trial [34] assessing the effect of omega-3
PUFA upon hyperactivity (but not inattention) involved a
group of children with autism. Autism is chiefly character-
ised by limited behaviour patterns, reduced social interac-
tion and delayed language, however hyperactivity is also
frequently observed [12]. Whether there is an aetiological
overlap between hyperactivity in ADHD and in autism is
unclear. The authors administered a supplement delivery
a daily dose of 800 mg of EPA and 700 mg of DHA or a
coconut oil placebo for 6 weeks (a considerably shorter
duration than most trials), and assessed psychopathology
using the Aberrant Behaviours Checklist [35]. Omega-3
PUFA showed no statistically significant benefit over pla-
cebo on any of the ABC scales including irritability, social
withdrawal, stereotypy, inappropriate speech or hyperac-
tivity. The authors highlight the fact that hyperactivity
showed the greatest difference relative to the placebo
group although much of the inter-group difference was
due to a worsening of hyperactivity during the trial in the
placebo group. The small size and short duration of the
trial are problematical and further trials will be required to
confirm or reject a previous observation obtained using
and open-label trial that omega-3 PUFA supplementation
is beneficial in autism [36].
The variety of disorders and outcome measures used in
the ADHD-related trials made direct comparison amongst
them difficult. Three trials [29,30,32] utilised comparable
measures of hyperactivity and inattention, however,
which allowed us to provide preliminary estimates of the
effect of omega-3 fatty acid supplementation on inatten-
tion and hyperactivity as assessed by parents and teachers
(Figure 1). These estimates are exploratory since the
grouping into separate parent-teacher and inattention-
hyperactivity categories was based on the available data,
not on any a priori hypothesis. Furthermore, there was not
sufficient comparable data to attempt to calculate an over-
all estimate of effect. From these limited data it appears
that teachers may tend to report a greater beneficial effect
than do parents, and that there may be a greater effect on
inattention than on hyperactivity.
In summary, omega-3 containing PUFA supplements did
not perform better than placebo in children with clinically
diagnosed ADHD, but may have had a modest effect on
attention and hyperactivity symptoms in children with
DCD. The data are, however, inconclusive at this time. A
trial of a similarly formulated supplement to that used in
the DCD trial [32] in clinically defined ADHD has not yet
been published. Such an experiment is needed to resolve
the question of whether omega-3 PUFA supplementation
is beneficial in ADHD, as are trials which take place over
longer time intervals. Finally, because the trials used a
variety of PUFA formulations, no conclusion can currently
be drawn regarding which omega-3 PUFA, if any, is most
effective.
Anxiety disorders
The investigation of the efficacy of omega-3 PUFA in anx-
iety disorders is a field in its infancy. Anxiety disorders
comprise a variety of disorders characterised by abnormal
fears and phobias such as panic disorder, generalised anx-
iety disorder, obsessive compulsive disorder and social
phobia [12]. To date only 2 placebo controlled trials have
been performed (Table 2). Omega-3 fatty acid supple-Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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mentation has been assessed using double blind, placebo
controlled trial in obsessive compulsive disorder (OCD),
as well as anxiety associated with substance use. Using a
crossover design Fux and colleagues [37] administered
placebo or 2 g/day ethyl EPA for 6 weeks followed by a liq-
uid paraffin placebo or EPA for a further 6 weeks to 11
patients with OCD. Symptoms were assessed using the
Yale-Brown Obsessive Compulsive Scale [38], the Hamil-
ton Depression Rating Scale (HDRS [39]) and the Hamil-
ton Anxiety Rating Scale [40]. The authors found no
significant difference compared to placebo treatment on
any of the scales and concluded that omega-3 fatty acids
were not efficacious (it is worth noting that depression
and anxiety symptoms in the patient groups were mild).
The study, however, utilized a very small sample size and
administered fatty acids for a much shorter time period
than used in the most other trials. As such, although this
trial reports a negative finding, its limitations leave open
the question of whether omega-3 PUFA have any efficacy
in OCD. A second recent trial has generated more positive
results although the findings should be considered as very
preliminary. In a double-blinded randomised trial
Buydens-Branchley and Branchley [41] administered
either a vegetable oil placebo or an omega-3 supplement
providing 2.2 g EPA and 0.5 g DHA/day to 24 men being
treated for substance use. Using a self-administered test
scale which assessed anger, tension and anxiety, and
mood (Profiles of Mood states scale [42]) the authors
report a significantly better improvement in the tension
and anxiety subscale compared to placebo. The use of
patients who do not have a clinically defined anxiety dis-
order is a limiting factor of the trial, as is the small size and
use of a self-rating scale. Thus, while these trials are not
conclusive with regard to the potential efficacy of omega-
3 PUFA supplementation, they do provide a rationale for
conducting further trials in populations with clinically
well defined anxiety disorders. Interestingly, anxiety was
also reduced in an open-label trial (i.e. a non-blinded trial
having with no placebo) of an omega-3/omega-6 PUFA
mixture is students writing their examinations [43]
whereas supplementation with 443 mg EPA and 319 mg/
day DHA for 2 months reduced plasma catecholamine
levels (adrenaline, noradrenaline and dopamine) relative
to those receiving a soybean lecithin placebo [44]. Such
an observation increases the biological plausibility of
omega-3 PUFA reducing the symptoms of anxiety given
the central role that the hypothalamic-pituitary-adrenal
axis (the major control mechanism for catecholamine
synthesis) in these disorders [6]. It is also of note that
reduced omega-3 PUFA abundance has recently been
reported in non-depressed patients with social phobia,
another form of anxiety disorder, opening up a further
avenue for clinical investigation [45].
Schizophrenia
Fatty acids have also been the focus of intense study in the
psychotic disorder schizophrenia [12]. Schizophrenia is a
severe mental illness with a prevalence of 1 – 2% [46] that,
like depression, has a complex and poorly understood
aetiology. The disease is episodic and is characterised by
two classes of symptoms: positive, which include halluci-
nations, delusions, disorganized thought and behaviour,
and negative, such as flattened mood, poverty of speech,
and deficits in goal directed behaviours which account for
most of the morbidity of the illness [47]. The disorder is
treated with a variety of anti-psychotic medications all of
which have limited efficacy (treatment of the debilitating
negative symptoms is poor) and significant side effects
including motor function, obesity and, more controver-
sially, diabetes [6]. More effective treatments are needed
for schizophrenia and a variety of different approaches
have been tried including one that postulates that schizo-
phrenia is associated with an abnormality in the cell
membrane, termed the phospholipid hypothesis [47]. A
large number of studies have examined fatty acid abun-
dance in the disorder [48] including reports of decreased
Standardized mean differences in ADHD-related symptoms  in omega-3 PUFA-treated compared to placebo-treated sub- jects Figure 1
Standardized mean differences in ADHD-related symptoms in 
omega-3 PUFA-treated compared to placebo-treated subjects. 
SMD are the standardized mean differences (scaled to stand-
ard deviations) in the change-from-baseline scores in the pla-
cebo and treatment groups, along with 95% confidence 
intervals. A summary of each study's characteristics can be 
found in Table 1. Because of the incomparability of the 
instruments used in several of the studies, we were only able 
to include three studies in this summary. We have shown 
separate estimates for hyperactivity and inattention sub-
scales, as well as distinguished parent and teacher ratings. 
There are not yet sufficient sufficiently comparable data to 
justify calculating an overall summary. We have, however, 
provided preliminary inverse-variance-weighted averages of 
the two studies in each subsection.
Teacher - Hyperactivity
Stevens et al 2003
Richardson & Montgomery 2005
Subtotal
Teacher - Inattention
Stevens et al 2003
Richardson & Montgomery 2005
Subtotal
Parent - Hyperactivity
Richardson & Puri 2002
Stevens et al 2003
Subtotal
Parent - Inattention
Richardson & Puri 2002
Stevens et al 2003
Subtotal
Study ID
0.36 (0.46, 1.17)
0.28 (0.11, 0.67)
0.30 (0.06, 0.65)
0.48 (0.34, 1.30)
0.36 (0.04, 0.75)
0.38 (0.03, 0.73)
0.10 (0.63, 0.83)
0.12 (0.81, 0.56)
0.02 (0.52, 0.48)
0.49 (0.25, 1.23)
0.05 (0.63, 0.74)
0.26 (0.25, 0.76)
Treatment worsens scores Treatment improves scores
0 1.3 0 1.3
Difference (95% CI)
Standardized MeanLipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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PUFA abundance of a variety of body tissues [49]. The
PUFA affected vary between studies leading to the recent
proposal that fatty acid alterations in the disorder are sec-
ondary to altered dietary intake occurring as a conse-
quence of the disease process [48].
Despite the inconsistent nature of the fatty acid abun-
dance data, a number of clinical trials utilising fatty acid
supplementation in schizophrenia defined according to
DSM criteria have been carried out. The earliest trials uti-
lized n-6 fatty acids, mainly gamma linoleic acid. The out-
come of these small studies was largely negative [49].
More recently, the efficacy of omega-3 fatty acids was
examined in a series of double blind trials. All the trials
utilised the Positive and Negative Syndrome Scale
(PANSS) [50] to monitor disease severity in patients with
similar baseline psychopathology (Table 3). Using a dou-
ble-blind placebo-controlled design, Peet and colleagues
[3] compared the effect of administering an EPA-enriched
oil containing 2 g/day EPA, a DHA-enriched oil contain-
ing 2 g/day DHA or a corn-oil placebo for 3 months upon
schizophrenic symptom onset in 45 patients who were in
receipt of conventional anti-psychotic medications. The
authors reported that at the end of the trial the PANSS
score in the EPA groups was significantly lower than in the
placebo group although the difference was not large
(Table 3). A comparison of change from baseline values
for omega-3 and placebo groups was not performed. In
addition, a significantly greater proportion of participants
in the EPA group had PANSS scores that improved by over
25% compared to that in the placebo and DHA groups.
This success criterion was not an a priori outcome meas-
ure, however, and, in any case, the clinical significance of
a 25% improvement in symptoms is unclear [51]. The
authors also conducted a second double-blind placebo-
controlled trial in which 26 unmedicated patients with
schizophrenia were treated with an EPA-enriched oil pro-
viding an equivalent of 2 g/day EPA for 3 months [3]. The
trial was unusual in that patients received conventional
antipsychotic medications if they required them during
the EPA treatment period, and as such the level and type
of medication of subjects tended to vary during the trial,
an important confound which hinders interpretation of
the findings. At the end of the trial the EPA treated group
had significantly lower PANSS scores than the corn-oil
placebo group, although again a change from baseline
comparison was not performed. Moreover, the difference
between active and placebo groups was not large (Table
3). The authors also report significantly fewer days on
antipsychotic treatment during the trial in the EPA group
and that at the end of the trial 4 out of 15 EPA-treated sub-
jects had not received any additional medication through-
out the trial, while all placebo-treated patients were
medicated with conventional drugs. While an interesting
finding, the short duration of the trial combined with the
episodic nature of the disorder makes it difficult to assess
the clinical relevance of such an observation.
Peet and Horrobin [52] followed up these trials with a
dose-ranging placebo-controlled double-blind study of 1,
2, or 4 g/day ethyl-EPA or a liquid paraffin placebo for 12
weeks in a group of 115 medicated patients with schizo-
phrenia. They report that 2 g/day EPA (but not 1 or 4 g/
day) improved change-from-baseline scores in patients
treated with the atypical antipsychotic clozapine, but not
in those treated with typical or non-clozapine atypical
antipsychotics [52]. Indeed, in those treated with typical
and non-clozapine atypical neuroleptics all doses of EPA
except one actually performed less well than placebo
(mean difference scores were positive). A clozapine-treat-
Table 2: Double blind placebo-controlled trials of omega-3 fatty acids upon in anxiety disorders.
Ref Jadad 
score
Disorder Meds Age Gen Omega-3 
fatty acid
Prep 
type
Duration N Outcome 
measure
Average 
baseline 
score
Δ Statistical 
significance vs. 
placebo
37 4 OCD 100% 34 73% 2 g/day 
EPA
Ethyl 
EPA
6 weeks 11 YBOCS 26 -0.9 No
HDRS 11 NS No
HARS 14 NS No
41 4 SUA 42% 51 0% 450 mg/
day EPA
100 mg/
day DHA
Crude 
mixture
3 
months
24 POMS-T 4.3 -2.9 Yes
OCD and SUA are obsessive compulsive disorder and substance use associated anxiety respectively. Δ refers to the change from baseline symptom 
scores for the omega-3 fatty acid group minus change from baseline scores for the placebo group. Jadad design quality scores can range from 0 to 5 
with 5 being best. The symptom scales used are the Yale-Brown Obsessive Compulsive Scale (YBOCS), Hamilton Depression Rating Scale (HDRS), 
Hamilton Anxiety Rating Scale (HARS) and the tension subscale of the Profile of Mood Scale (POMS-T). Zero is best for all scales hence a negative 
Δ value indicates an improvement over placebo. The average baseline score is the average of the omega-3 and placebo group scores at the start of 
the trial. Gen (gender) refers to the % of female participants in the trial. Meds refers to the percentage of trial participant who were in receipt of 
conventional medications for anxiety disorders. Prep. type describes whether a crude oil mixture or a purified fatty acid was used. NS – not stated.Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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ment specific effect of EPA in schizophrenia seems
unlikely and instead may be due to chance alone. The
authors do not state the effect of EPA when all the medi-
cation groups are combined. Using the data presented in
the paper the change-from-baseline values for EPA and
placebo groups can be calculated (Table 3). Assuming a
normal distribution of the data it is also possible to calcu-
late 95% confidence intervals for the difference between
placebo EPA-treated groups these being for 1 g/day EPA: -
4.7 to + 6.7; 2 g/day EPA: -12.7 to +1.8; 4 g/day EPA: -2.7
to +10.2. Since all of these intervals contain the value zero
i.e. no difference between active and placebo groups, it is
likely that none of the EPA doses significantly improved
symptoms compared to placebo when subjects are ana-
lysed as a whole.
Besides the researchers lead by Peet, two other groups
have investigated the use of EPA in schizophrenia using
double-blind placebo controlled trials. Fenton and col-
leagues [53] administered either 3 g/day ethyl-EPA or a
mineral oil placebo to 87 medicated patients with schizo-
phrenia for 16 weeks. They observed no significant differ-
ence in PANSS scores between the EPA and placebo
groups at any of the time points reported (1, 2, 4, 8, 12 or
16 weeks). It has been argued that erythrocyte EPA levels
rose significantly in the placebo group, suggesting that the
informed consent procedure lead to participants consum-
ing omega-3 fatty acid rich foods or taking fish oils sup-
plements thereby defeating the placebo element [54]. It is
unlikely that such an explanation explains the lack of
effect given that the change from baseline symptom scores
in both placebo and omega-3 groups were low compared
to other trials, and that change in EPA abundance in the
placebo group was not correlated to clinical improvement
[55]. Another trial [56] used a higher dose of ethyl-EPA (3
g/day for 12 weeks) which was compared to a liquid par-
affin placebo administered to 40 medicated patients with
schizophrenia. These authors reported a significant posi-
tive difference in symptom scores in the placebo and EPA
groups after 3, 9 and 12 weeks. Moreover, in contrast to
Peet and Horrobin [52], these researchers report that the
largest reduction in PANSS scores is observed in those
patients taking typical antipsychotics, not the atypical
drug clozapine, although the difference did not reach sta-
tistical significance. It should be noted, however, that
despite the fact that the authors' main a priori outcome
measure was intended to be scores at 12 weeks, the differ-
ence between the two groups had in fact diminished by
Table 3: Double-blind placebo controlled trials of omega-3 fatty acids in schizophrenia.
Ref Jadad score Meds Age Gender Omega-3 fatty 
acid
Prep. type Duration N Average 
baseline 
score
Δ Statistical 
significance 
vs. placebo
3 5 100% 43 38% 2 g/day EPA Crude mixture 12 weeks 29 75 -4.1 Yes
43 29% 2 g/day DHA Crude mixture 12 weeks 40 73 +2.2 No
35 0 % 1 35 40% 2 g/day EPA Crude mixture 12 weeks 26 75 -3.6 Yes
52 5 100% (typical) 39 54% 1 g/day EPA Ethyl ester 12 weeks 21 74 +7.0 No
37 47% 2 g/day EPA Ethyl ester 12 weeks 17 75 +4.2 No
38 57% 4 g/day EPA Ethyl ester 12 weeks 22 77 +2.5 No
100% (atypical) 39 54% 1 g/day EPA Ethyl ester 12 weeks 23 76 +5.2 No
37 47% 2 g/day EPA Ethyl ester 12 weeks 26 82 -0.9 No
38 57% 4 g/day EPA Ethyl ester 12 weeks 23 81 +10.6 No
100% (clozapine) 39 54% 1 g/day EPA Ethyl ester 12 weeks 16 79 -10.1 No
37 47% 2 g/day EPA Ethyl ester 12 weeks 16 81 -17.8 Yes
38 57% 4 g/day EPA Ethyl ester 12 weeks 13 74 -6.9 No
100% (all meds) 39 54% 1 g/day EPA Ethyl ester 12 weeks 60 77 -1.02 No2
37 47% 2 g/day EPA Ethyl ester 12 weeks 59 78 +5.42 No2
38 57% 4 g/day EPA Ethyl ester 12 weeks 58 77 -3.72 No2
53 4 100% 40 39% 3 g/day EPA Ethyl ester 12 weeks 87 75 +2.0 No
16 weeks 87 +1.0 No
56 3 100% 45 NS 3 g/day EPA Ethyl ester 9 weeks 40 75 -9.5 Yes
12 weeks 40 -7.33 Yes
Δ is refers to the change from baseline symptom scores for the omega-3 fatty acid group minus change from baseline scores for the placebo group. 
Jadad design quality scores can range from 0 to 5 with 5 being best. The symptom scale used in all the trials is the Positive and Negative Symptom 
Scale (PANSS). Zero is best for this scale hence a negative Δ value indicates an improvement over placebo. The average baseline score is the 
average of the omega-3 and placebo group scores at the start of the trial. Gen (gender) refers to the % of female participants in the trial. Meds 
refers to the percentage of trial participant who were in receipt of conventional medications for schizophrenia. Prep. type describes whether a 
crude oil mixture or a purified fatty acid was used. Notes: 1Although trial participants were not in receipt of medication at commencement, they 
were giving anit-psychotic medications as required during the trial. 2The primary outcome measure was stated by the authors to be 12 weeks, but 
this was not reported in the text; therefore this estimate is an approximation based on Figure 1 in Emsley and colleagues [56]. 3 Calculated from 
Tables 6 – 8 in Peet and Horrobin [52].Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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this time point. Unfortunately, the statistical analysis and
trials outcomes were only reported in detail for the 9 week
scores, although the authors do not highlight this point in
their analysis. The failure to use the a priori outcome meas-
ure, along with deficits in other reporting aspects of the
trial, diminishes our confidence in the robustness of this
trial's findings.
In general, clinical trials of omega-3 fatty acids in schizo-
phrenia, despite being mostly of high quality, have pro-
duced inconsistent results and small effects sizes of
doubtful clinical significance. Although the trial by Peet
and Horrobin [52] does report a significant improvement,
this only occurs at one dose in a group of patients having
a specific background treatment. Taken as a whole, the
evidence suggests that omega-3 fatty acids little or no
effect upon the symptoms of schizophrenia, and that even
if a true effect exists, that it is unlikely to be clinically rel-
evant.
Personality disorders
Personality disorders (also known as axis-2 disorders) are
a type of mental illness in which patients form inflexible
patterns of actions and thoughts [12]. They are generally
treated using various forms of psychotherapy although
pharmacological treatments are commonly used for
attending symptoms such as depression or anxiety. To
date the efficacy of omega-3 PUFA has only been tested in
one type of personality disorder, borderline personality
disorder (BPD). Zanarini and Frankenburg [57] adminis-
tered 1 g/day ethyl EPA or placebo to 30 subjects with the
disorder for 8 weeks and assessed aggression and depres-
sion using the Modified Overt Aggression Scale (MOAS
[58]) and the Montgomery-Asberg Depression Rating
Scale (MADRS [59]) respectively. The authors' conclusion
that "ethyl EPA was superior to placebo in diminishing
aggression as well as the severity of depressive symptoms"
is surprising given the data presented in the research
report. For the MOAS the difference between change in
baseline values between placebo and omega-3 PUFA
groups was only -0.8 and for MADRS -1.5 which does not
support the authors conclusions. Based on the published
data we find that there is little evidence to support the use
of omega-3 fatty acids in the treatment of BPD.
Major depressive disorder
Major depressive disorder (MDD) is a serious affective ill-
ness [12] with a lifetime prevalence estimated to be
between 5 and 11% of the population [60]. It is character-
ized by depressed mood, a loss of interest in pleasurable
activities, changes in sleep patterns and weight, and
reduced cognitive abilities and concentration. A signifi-
cant proportion of persons (approximately 15%) with
severe depression eventually commit suicide making it the
seventh most frequent cause of death in the US [61]. Epi-
sodes can last up to several years and the illness has a high
recurrence rate ranging from 50% after one episode to
90% for those with 3 or more occurrences [61]. Depres-
sion is most commonly treated with a variety of antide-
pressant drugs such as the selective serotonin reuptake
inhibitors (SSRI) and tricyclic antidepressants. Most treat-
ments have a response rate, defined as a 50% improve-
ment in symptoms, of approximately 66%, and around
80–90% of patients eventually respond to some treatment
[60]. However, a significant proportion (10 – 20%) of
patients are treatment refractive i.e. they do not respond at
all or respond poorly to therapy. Moreover, the propor-
tion of successfully treated patients who stay well for even
18 months is disappointingly low, being around 70%
[60]. These statistics indicate that there is much room for
improvement in the treatment and prevention of depres-
sion. Such advances are difficult because the disease has a
complex biological, psychological and sociological aetiol-
ogy. Diet has been postulated to be involved and it has
been argued that the rising rates of MDD [62] are at least
partly due to a decreased consumption of omega-3 fatty
acids, these having been replaced in the diet by omega-6
fatty acids [63,64]. In support of this hypothesis, studies
of patients with major depressive disorder have shown a
striking and consistent deficit in omega-3 fatty acid abun-
dance, while omega-6 PUFA levels are largely unaffected
[65]. These findings do not appear to be easily explained
by such potentially confounding factors as antidepressant
medication or smoking [48]. Epidemiological studies
have suggested that omega-3 PUFA deficits may be due to
decreased dietary intake, although metabolic dysfunction
has also been postulated [65].
Such studies have lead several investigators to conduct
clinical trials of omega-3 fatty acids in patients with
depressive disorders (Table 4). The trials were not of a uni-
form quality, however, as assessed by Jadad scores which
ranged from 2 to 5. Peet and Horrobin [66] carried out the
first double-blind placebo-controlled trial testing omega-
3 fatty acids in MDD. They administered 1, 2 or 4 g/day
ethyl-EPA or a liquid paraffin placebo for 12 weeks to 70
patients with MDD who had persistent symptoms of
depression despite the use of conventional anti-depres-
sant drugs. They report that 1 g/day, but not 2 or 4 g/day
ethyl-EPA, was significantly more likely than placebo to
improve symptoms rated using the HDRS, the MADRS
and the Beck Depression Inventory [67], with the effect
being apparent at the earliest time point recorded, 4
weeks. The magnitude of the difference between omega-3
and placebo groups was, however, small. For example,
ethyl EPA reduced the HDRS score by 3.8 points more
than placebo. Peet and Horrobin [66] also report that a
higher proportion of patients receiving 1 g/day achieved a
50% improvement in their symptoms (considered to be
clinically significant) compared to the placebo group (9/Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
Page 10 of 19
(page number not for citation purposes)
17 vs. 5/17). The statistical significance of this difference
was not reported, but can be calculated as being not sig-
nificant (p = 0.163 for a two-sided test of proportions; p =
0.082 for the one-sided test).
An apparent antidepressant effect of ethyl-EPA was also
reported by Nemets and colleagues [68]. These investiga-
tors used a 2 g/day dose of ethyl-EPA or undefined pla-
cebo for 4 weeks, administered to 20 medicated patients.
They observed a significant reduction in symptoms meas-
ured using the HDRS in the EPA compared to the placebo
group after 2 and 3 weeks of treatment as well as the main
outcome measure duration of 4 weeks. The authors base
their statistics on a per-protocol analysis which excludes
participants who did not complete the trial, rather than
the more acceptable intent-to-treat analysis. We have
therefore performed such an analysis using the data con-
tained in the report (Table 4) and find that the intent-to-
treat analysis shows a slightly larger effect than the per-
protocol analysis, which lends further support to the
authors' conclusions. Furthermore, a significantly higher
proportion of patients achieved a 50% reduction in symp-
toms in the EPA compared to the placebo groups (60% vs.
10% respectively). A beneficial effect of omega-3 fatty
acids is also reported by Su and colleagues [69] who con-
ducted a shorter duration 8 week double-blind placebo-
controlled trial of 22 patients with MDD (all but 2 were
currently medicated) using fish oil (which resulted in a
daily dose of 2.2 g/day EPA and 1.1 g/day DHA) or an
olive oil placebo. Of the patients completing the trial (the
authors only provide the data for a per-protocol analysis;
4 placebo- and 2 intervention-allocated participants
dropped out of the study), the omega-3 fatty acid group
achieved a significantly greater reduction in depressive
symptoms than the placebo group.
Most recently, omega-3 PUFA supplementation is
reported to be beneficial in depression occurring in chil-
dren. Childhood depression is less common than that in
adults but is nevertheless estimated to affect 2 – 4% of
children [70]. Nemets and colleagues [71] administered
400 mg EPA and 200 mg DHA daily (or 380 mg DHA and
180 mg DHA daily in a smaller capsule size) or a safflower
oil placebo to 28 children who were currently depressed.
The children were assessed every 4 weeks for 16 weeks
using the Children's Depression Rating Scale (CDRS) [72]
and Clinical Global Impression scale (CGI) [73]. The
omega-3 PUFA group showed significant improvement
compared to the placebo group using both the CDRS and
GGI. The trial is also of note since the participants were
not in receipt of conventional anti-depressant treatments
although 5 were being treated for symptoms of ADHD
with methylphenidate. One other trial has been con-
ducted which also utilised an omega-3 PUFA as a mono-
therapy for depression (as opposed to being an adjunct to
conventional antidepressants), although in this trial no
beneficial effect of omega-3 PUFA supplementation was
observed. Specifically, Marangell and colleagues [74]
reported that 2 g/day DHA administered to 18 patients
with MDD for 6 weeks did not improve symptom scores
relative to 17 patients who received an undefined placebo.
The trial differed from the previous studies reporting pos-
itive findings in that the authors used a preparation high
in DHA, rather than high EPA content oils or ethyl-EPA.
The nature of the DHA or placebo preparations are not
described (contributing to a low Jadad score), although it
is likely to that the former was a crude oil preparation
given that 14 patients receiving DHA, but no patients in
the placebo group, reported a "fish" aftertaste. A second
trial reporting negative findings also utilised a DHA-rich
oil [75] in which 77 patients with depression received
either 2.4 g/day DHA and 0.6 g/day EPA or an olive oil
placebo. Unlike the other trials described the authors
included participants in the trial based on their HDRS
score rather than by psychiatric interview and, as a conse-
quence, the participants are likely to be more heteroge-
nous in nature and may not have had true MDD according
to DSM-IV criteria. Although a significant reduction in
symptoms rated using the HDRS occurred in the omega-3
fatty acid group, no difference was apparent between pla-
cebo and omega-3 PUFA groups. It is important to note,
however, that on average, the participants in this trial were
only mildly depressed (baseline HDRS was 12 compared
to an average of 21 for the other trials), which led to both
the placebo and DHA groups achieving a cure rate (no sig-
nificant depressive symptoms) approaching 100%. Such a
high cure rate in both groups, whether because of a strong
placebo effect or because of a lack of pathology at base-
line, prevents us from drawing any firm conclusions
regarding the efficacy of omega-3 PUFA in depression
from this trial.
Bipolar disorder
Like MDD, bipolar disorder (BD) is a disease of mood
[12]. It is less prevalent than MDD, with a lifetime risk of
1–2%, and differs from MDD in that BD patients experi-
ence both depressive symptoms and emotional highs
termed manic episodes [76]. Manic symptoms include
inflated self-esteem that may reach delusional propor-
tions, a decreased need for sleep, rapid speech and
thoughts, and an inability to remain focused. BD is a seri-
ous and sometimes life threatening illness that is com-
monly treated using either lithium or anti-convulsant
mood stabilizers such as valproic acid [6]. The investiga-
tion of omega-3 fatty acid abundance in BD is limited to
only three studies which, although suggestive of a mild
deficit of omega-3 PUFA in BD, are rather inconsistent
and certainly not on par with the pronounced deficit
observed in MDD [48]. Nevertheless, Stoll and colleagues
[77] reported that, compared to those receiving an oliveLipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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oil placebo, patients with BD who had received fish oils
containing 6.2 g/day EPA and 3.4 g/day DHA for at least
30 days were significantly less likely to relapse (i.e. require
changes in their treatment necessitating exit from the
trial) (Table 4). The investigators also observed that the
omega-3 fatty acid group had a better response than pla-
cebo in terms of depressive symptoms (rated using the
HDRS) and overall pathology (using the Clinical Global
Impression and Global Assessment Scales [78]), but not
in terms of manic symptoms assessed using the Young
Mania Rating Scale (YMRS [79]). Although small is size,
the study did indicate a potentially beneficial effect of
omega-3 fatty acids in BD, particularly in the depressive
phase of the disorder, suggesting a similar mechanism to
that which underlies the possible antidepressant effects in
MDD. A depressive phase effect is also indicated by a later
trial conducted by Frangou and colleagues [80]. These
investigators conducted a high quality (Jadad score = 5)
double-blind placebo-controlled trial of 75 medicated
outpatients with bipolar disorder who were administered
either 1 g or 2 g/day ethyl EPA or placebo for 12 weeks.
They report that neither dose of EPA had any statistically
significant effect upon mania (assessed using the YMRS),
but both EPA doses resulted in a non-statistically signifi-
Table 4: Double blind placebo-controlled trials of omega-3 fatty acids upon in mood disorders.
Ref Jadad 
score
Disorder Meds Age Gen Omega-3 fatty 
acid
Prep type Duration N Outcome 
measure
Average 
baseline 
score
Δ Statistical 
significant 
difference
66 5 MDD 100% 50 81% 1 g/day EPA Ethyl 
ester
12 
weeks
34 HDRS 20 -3.8 Yes
2 g/day EPA Ethyl 
ester
12 
weeks
35 HDRS 20 +0.3 No
4 g/day EPA Ethyl 
ester
12 
weeks
34 HDRS 19 -0.3 No
68 3 MDD 100% 53 85% 2 g/day EPA Ethyl 
ester
4 weeks 20 HDRS 22 -10.8 Yes
69 4 MDD 100% 38 80% 2.2 g/day EPA
1.1 g/day DHA
Crude 
mixture
8 weeks 22 HDRS 22 -7.2 Yes
71 4 CD 0% 10 25% 0.4 g/day EPA1
0.2 g/day DHA
Crude 
mixture
16 
weeks
20 CDRS 69 -25 Yes
74 2 MDD 0% 47 80% 2 g/day DHA Crude 
mixture
6 weeks 35 HDRS 26 -2.3 No
75 3 MDD 79% 39 79% 0.6 g/day EPA
2.4 g/day DHA
Crude 
mixture
12 
weeks
77 HDRS 12 +0.6 No
77 3 BD 100% 43 66% 6.2 g/day EPA
3.4 g/day DHA
Crude 
mixture
4 
months
30 YMRS 7 +1.3 No
HDRS 11 -7.7 Yes
80 5 BD 100% 47 76% 1 g/day EPA Ethyl 
ester
12 
weeks
50 YMRS 6 -3.62 No
HDRS 15 -3.6 No
2 g/day EPA Ethyl 
ester
12 
weeks
51 YMRS 5 -12 No
HDRS 15 -3 No
1 and 2 g/day 
groups 
combined
Ethyl 
ester
12 
weeks
51 YMRS 6 -2.32 No
HDRS 15 -3.3 Yes
81 5 BD 100% 45 85% 6 g/day EPA Ethyl 
ester
16 
weeks
116 IDS NS -0.4 No
YMRS NS +0.6 No
86 5 PPD 0% 31 100
%
0.2 g/day DHA Crude 
mixture
4 
months
89 BDI 7 +0.4 No
MDD, CD, PPD and BD are major depressive disorder, childhood depression, post partum depression and bipolar disorder respectively. Δ refers 
to the difference between the change from baseline values for placebo and treatment groups (change from baseline symptom scores for the omega-
3 fatty acid group minus change from baseline scores for the placebo group). Since for all scales zero is better, a negative value indicates a better 
than placebo response. Trial quality was assessed using Jadad design quality scores which can range from 0 to 5 with 5 being best. Outcome 
measures are HDRS: Hamilton Depression Rating Scale, YMRS: Young Mania Rating Scale, CDRS – Children's Depression Rating Scale, IDS – 
Inventory of Depressive Symptomatology. The average baseline score is the average of the omega-3 and placebo group scores at the start of the 
trial. Age refers to the mean age in years of the active and placebo groups. Gen (gender) refers to the % of female participants in the trial. Notes: 1 
Some children received a different capsule size resulting in a dose of 0.38 g EPA/day and 0.18 g DHA/day, 2 Although the omega-3 fatty acid group 
performed better than placebo on the YMRS it should be noted that the mania symptoms worsened in both omega-3 PUFA and placebo groups 
during the trial.Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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cant decline in symptoms of depression (assessed using
the HDRS). The authors report that by combining the two
EPA groups and comparing them to the placebo group,
then EPA shows a statistically significant effect upon
depressive symptoms, but mania symptoms were still
found to be unchanged. The need to combine the doses of
EPA to obtain a statistically significant improvement is
indicative of EPA having a rather small effect upon depres-
sive symptoms. Additionally, it is worth noting that in
MDD, the results of Peet and Horrobin dose-ranging trial
indicated that an EPA dose of 2 g/day was not efficacious
[66] (Table 4).
The most recent trial involving subjects with bipolar dis-
order focussed on two subgroups, those with a current
major depressive episode and those with rapid-cycling ill-
ness (patients who switch quickly between manic and
depressed states). Keck and colleagues [81] administered
either 6 g/day ethyl-EPA or a liquid paraffin placebo to 95
patients with bipolar depression or 86 patients with rapid
cycling bipolar disorder. The authors report no benefit of
omega-3 PUFA treatment relative to the placebo for either
mania or depression, assessed using the YMRS and the
Inventory of Depressive Symptomatology respectively
[82], or on time to withdrawal from the trial. Data are pre-
sented only for the results of the two bipolar groups com-
bined although the report states that the diagnostic
subtype i.e. depressed and rapid cycling did not affect
treatment response. Whiles this precludes any further
analysis of the treatment effects upon bipolar subtypes,
the data reported are comparable to the other bipolar dis-
order trials since they also did not differentiate by sub-
type. The dose of EPA used in the trial by Keck and
colleagues (6 g/day) was approximately the same as that
used in the Stoll and colleagues trial, but differed in that
Keck and colleagues administered purified ethyl-EPA [81]
while Stoll and colleagues co-administered EPA with 3.4
g/day DHA. Given that higher doses of purified EPA were
found to be ineffective in MDD [66], it is possible that the
negative data reported by Keck and colleagues [81] is due
to using too high a daily dose of the lipid in the absence
of sufficient quantities of DHA or other component of the
crude oil. Finally, a fourth placebo controlled trial of
omega-3 PUFA in bipolar disorder has been published
[83]. This trial was, however, limited to reports of compli-
ance and adverse events with no psychopathology being
included. We therefore did not consider this trial further.
The results of the bipolar disorder trials are somewhat
supportive of an anti-depressant effect of omega-3 fatty
acids similar to that observed in MDD, although one trial
did reported omega-3 PUFA to be ineffective. One con-
cern of treating depression in patients with bipolar disor-
der is that the therapy will exacerbate manic episodes.
However none of the trials indicated that omega-3 PUFA
has any effect upon mania, either negative or positive.
Since all trials utilized supplements containing predomi-
nantly EPA, no conclusions can be drawn with respect to
the relative efficacy in BD, if any, of the various species of
omega-3 PUFA.
Post-partum depression
There is evidence of omega-3 PUFA deficiency in women
who develop postpartum depression (PPD) [84]. PPD is a
serious mood disorder with the same symptoms as MDD
but which occurs in the postpartum period. Women who
developed PDD are reported to have decreased levels of
omega-3 fatty acids, but normal omega-6 fatty acid abun-
dance [84]. This finding is particularly interesting because
the participants had reduced omega-3 fatty acid abun-
dance prior to the onset of depression, indicating that
omega-3 fatty acid deficiency may be predictive for the
occurrence of depression, and suggesting the possible util-
ity of early nutritional and/or conventional pharmacolog-
ical intervention to reduce the risk of PPD. The use of
omega-3 fatty acids as an antidepressant in pregnancy
would be attractive given the growing evidence that con-
ventional antidepressants may have an adverse effect
upon the child [85]. This, along with the promising results
of omega-3 fatty acid therapy obtained in MDD, has
prompted researchers to investigate their use in PPD. One
group of investigators [86] administered 200 mg/day of
DHA in the form of algal triglycerides or an undefined
placebo to 138 pregnant women using a randomized dou-
ble blind design. Depressive symptoms were monitored
using the self-rated Beck Depression Inventory before and
3 weeks, 2 months and 3 months after delivery. The Beck
scale is not a diagnostic instrument and only a subset of
participants were assessed for present and past incidence
of MDD using a structured clinical interview. The study
reported that DHA treatment did not differ from placebo
in terms of depressive symptoms assessed using the Beck
scale, leading the authors to conclude that DHA does not
reduce the incidence of PPD. Furthermore, among the
patients who underwent the structured clinical interview,
the incidence of current depression did not differ between
the DHA and placebo groups [86]. It should be noted,
however, that the women studied had, as a group, mini-
mal depressive symptoms at the start of the trial and only
a small proportion actually became depressed. As such the
trial does not answer the questions of whether administra-
tion of omega-3 PUFA may be useful once a woman has
actually developed PPD. Furthermore, given the results
obtained with MDD, it is possible that 200 mg/day DHA
is insufficient for even prophylactic use. Treatment of
diagnosed PPD with omega-3 fatty acids has been studied
using two open-label studies that reported both positive
[87] and negative results [88]. A placebo-controlled trial
utilizing higher doses of omega-3 fatty acids would be of
great interest.Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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Meta-analysis of effect upon depression
The use of the comparable ratings of depression by most
investigators allowed us to compare the trials to deter-
mine if there was evidence that omega-3 PUFA had a sig-
nificant mood-elevating effect in either MDD or bipolar
disorder. Combining all of the MDD and bipolar trials
using meta-analytical techniques shows that omega-3
fatty acid supplementation is significantly more effective
than placebo in the treatment of depression (Figure 2).
The magnitude of that effectiveness is approximately 0.91
standard deviations of improvement, given the character-
istics of the populations studied to date and noted above.
Such a finding is in line with a previously reported meta-
analysis which analysed a smaller number of trials [89].
There was, however, significant heterogeneity between the
studies. We noted three possible factors that might influ-
ence that heterogeneity (baseline HDRS score, depression
type and predominant omega-3 PUFA species) and tested
their effects on the overall estimate using random effects
meta-regression (Table 5). This analysis showed that the
primary factor responsible for heterogeneity in the com-
bined effect estimate is the PUFA species utilised. When
PUFA species is taken into account the amount of
between-study variance (τ2) is markedly reduced. The pre-
dicted overall standardised mean difference (i.e. SMD: the
mean difference between PUFA and placebo groups scaled
to the standard deviation) of EPA or a predominantly EPA
mixture were used would be 1.18, whereas for a DHA or
predominantly DHA mixture, the predicted overall SMD
would be 0.06 (Wald test for difference: p = 0.007). This
suggests that EPA, rather than DHA, is efficacious in the
alleviating the symptoms of depression, with an SMD
value suggesting that EPA has a major effect upon the
symptoms of depression. Two points should be note how-
ever. Firstly, as we have previously discussed, the negative
DHA trial conducted by Silvers and colleagues [75] may
have encountered a ceiling effect in terms of antidepres-
sant action. Secondly, Marangell and colleagues [74] uti-
lised DHA as monotherapy whereas adjunct omega-3
PUFA therapy was used in the other adult depression tri-
als. Thus, an alternative explanation for the lack of
observed efficacy is that omega-3 fatty acids (DHA or EPA)
may only be effective when given in combination with
other antidepressant medications, possibly by altering the
pharmacokinetics of the other drugs. On the other hand,
EPA administered in the absence of conventional antide-
pressants did show an antidepressant effect in childhood
depression suggesting that EPA does indeed have an
intrinsic efficacy. Thus although the available evidence is
suggestive that EPA plays a more significant role in the
antidepressant effect of omega-3 PUFA than does DHA,
until a trial specifically designed to test this hypothesis is
conducted this will remain an open question. Moreover,
the lack of an antidepressant effect of EPA administered in
purified form in bipolar depression should temper any
move to conclude that EPA is solely responsible for any
possible efficacy.
Possible mechanisms underlying the psychoactive effects 
of omega-3 PUFA
The clinical trials data is therefore supportive of n-3 PUFA
playing a significant role in mood disorders, while provid-
ing weaker support for their ability to enhance attention
and reduce anxiety, and little or no support for the amel-
ioration of the symptoms of schizophrenia. Furthermore,
for mood disorders, there is some evidence that EPA is
more efficacious then DHA in reducing the symptoms of
depression. We will now briefly consider whether the psy-
choactive characteristics of omega-3 PUFA are biologically
plausible from a neuroscientific perspective, and how the
findings emanating from the clinical trials might be
explained [6]. A useful means to consider these questions
Table 5: Meta-regression to identify factors that account for significant heterogeneity in the overall standardized mean difference 
(SMD) between PUFA treatment and placebo upon depression in patients with major depressive disorder or bipolar disorder.
Factor in Model Factor category Between-study 
variance (τ2)
SMD for category P(difference = 0)
No factor 0.39 0.91 NA
Baseline mean HDRS score <17 0.31 0.48 0.291
>17 1.01
Depression type Bipolar 0.48 0.80 0.761
MDD 0.98
PUFA species utilised Predominantly DHA 0.18 0.06 0.009
Predominantly EPA 1.18
Meta-regression models the effect of study variables on the between-study variance (τ2) in a random effects meta-analysis. To conserve degrees of 
freedom, each factor was tested independently. A smaller τ2 compared to the no-factor base model indicates that the factor explains more 
between-study variance. A meta-regression model also allows us to calculate a Wald test for the difference in the SMD for each category of the 
explanatory factor. A p-value less than 0.05 indicates that there is a statistically significant difference between the SMD for each category. All trials 
listed in Table 4 were included in the analysis of PUFA species utilised and depression type. For those studies using the HDRS, we used a baseline 
mean depression score of 17 as the cut-off value for moderate vs. mild depression [89]. The analysis of baseline depression scores excluded two 
trials – the trial conducted by Keck and colleagues [81] who did not report baseline scores, and the trial by Nemets and colleagues [71] because it 
used the Children's Depression Rating Scale and there is no agreement on what score constitutes moderate depression. NA – not applicable.Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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is to utilize the insight gained from almost six decades of
use and study of existing pharmacological interventions.
For mood and/or anxiety disorders current treatments
include compounds which enhance either serotonergic
neurotransmission e.g. SSRI, noradrenergic neurotrans-
mission e.g. selective noradrenergic reuptake inhibitors,
monoamine oxidase inhibitors, or both e.g. tricyclic anti-
depressants [6]. These drugs are thought to exert their ben-
eficial effects by increasing the influence that neurons,
originating in the locus coeruleus or dorsal raphe, have
upon their targets in the limbic system, thalamus and pre-
frontal cortex [6]. The efficacy of these drugs is thought to
derive from their ability to enhance serotonergic or
dopaminergic neurotransmission, whereas antagonism of
specific receptors of serotonin, dopamine or acetylcholine
by some compounds are believed to be responsible for
their unwanted side-effects [6]. In the case of attentional
disorders the treatment of choice is methyphenidate. This
compound most likely acts as a form of cognitive
enhancer by means of increasing dopaminergic neuro-
transmission within the mesocortical dopamine system
which projects from the ventral tegmentum in the mid-
brain to the prefrontal cortex [6]. In the case of schizo-
phrenia, however, medications are thought to work by
doing the opposite, that is, by reducing rather than
enhancing dopaminergic neurotransmission. Thus, both
typical and atypical antipsychotic drugs are thought to
diminish the positive symptoms of schizophrenia by
antagonizing dopamine D2 receptors within the mes-
olimbic dopamine system, a projection which originates
in the mid brain and terminates in the nucleus accumbens
and amygdala [6]. Moreover, agents which increase
dopaminergic neurotransmission can induce psychosis in
healthy individuals and actually worsen symptoms in
patients with schizophrenia [6]. In addition, some evi-
dence suggests that the same dopaminergic agents that
worsen symptoms of schizophrenia possess antidepres-
sant properties although this remains a matter of some
controversy [90]. It would therefore be very surprising
indeed if any medicinal compound was found to be a
beneficial treatment for the core symptoms of both schiz-
ophrenia  and  mood disorders. Moreover, if omega-3
PUFA were found to enhance dopaminergic and/or sero-
tonergic neurotransmission, then the existing pharmaco-
logical data would predict that they should be effective in
the treatment of mood, attentional and anxiety disorders.
The literature is, however, ambivalent. An extensive series
of experiments conducted by Chalon and colleagues [91]
has indicated that omega-3 PUFA deficiency beginning in
utero results in a reduced ability of neurons to (i) release
dopamine in the frontal cortex and nucleus accumbens in
response to tyramine, and (ii) release serotonin in the hip-
pocampus in response to fenfluramine [92,93]. Moreover,
n-3 PUFA deficiency in rats can result in altered cortical
dopamine D2 receptor density, a decreased number of
dopamine containing vesicles in each synapse, decreased
binding to the vesicular monoamine transporter and
increased dopamine metabolism, all of which are indica-
tive of decreased dopaminergic activity [93-95]. Such
findings do suggest that supplementation with omega-3
PUFA should enhance, or restore, dopaminergic and/or
serotonergic neurotransmission, and are hence supportive
of a significant role for omega-3 PUFA in mood, anxiety
and attentional disorders, but, importantly, not in schizo-
phrenia. It should be noted, however, that the model used
by Chalon and colleagues [91] results in a much more
severe omega-3 PUFA deficiency, starting in utero, than is
observed in, for example, patients with mood disorders
[48,65]. Moreover, animal behavioural data is not consist-
ent with the anti-dopaminergic effect of omega-3 PUFA
deficiency suggested by the neurochemical investigations
[96]. Using a similar model to Chalon and colleagues
[91], but which resulted in a milder omega-3 PUFA defi-
ciency, Levant and colleagues reported that rats deficient
in omega-3 PUFA in utero and after birth exhibited
increased basal locomotor activity and decreased cata-
lepsy in response to haloperidol [96], both of which are
suggestive of elevated, rather than decreased, basal
dopaminergic activity in omega-3 PUFA deficient ani-
Standardized mean differences in depressive symptoms in  omega-3 PUFA-treated compared to placebo-treated sub- jects with major depressive disorder or bipolar disorder Figure 2
Standardized mean differences in depressive symptoms in 
omega-3 PUFA-treated compared to placebo-treated sub-
jects with major depressive disorder or bipolar disorder. 
SMD are the standardized mean differences (scaled to stand-
ard deviations) in the change-from-baseline scores in the pla-
cebo and treatment groups, along with 95% confidence 
intervals. A summary of each study's characteristics can be 
found in Table 4. All studies rated patients using the HDRS, 
except that conducted by Llorente and colleagues [73], 
which was therefore excluded from the analysis. I-squared is 
the proportion of variance attributable to the heterogeneity 
between studies, and the p-value is for Cohen's Q, a test of 
the statistical significance of that heterogeneity. The overall 
estimate is the inverse-variance-weighted average of the 
studies based on a random effects model.
Overall (I-squared = 75.1%, p < 0.001)
Nemets et al 2002
Keck et al 2006
Nemets et al 2006
Peet et al 2002
Study ID
Su et al 2003
Silvers et al 2005
Frangou et al 2006
Stoll et al 1999
Marangell et al 2003
0.91 (0.41, 1.42)
1.53 (0.52, 2.54)
0.38 (2.97, 3.73)
2.45 (1.26, 3.64)
0.65 (0.18, 1.11)
2.07 (1.01, 3.12)
0.12 (0.57, 0.33)
0.67 (0.10, 1.24)
1.02 (0.25, 1.78)
0.28 (0.38, 0.95)
0.91 (0.41, 1.42)
1.53 (0.52, 2.54)
0.38 (2.97, 3.73)
Standardized Mean
2.45 (1.26, 3.64)
0.65 (0.18, 1.11)
Difference (95% CI)
2.07 (1.01, 3.12)
0.12 (0.57, 0.33)
0.67 (0.10, 1.24)
1.02 (0.25, 1.78)
0.28 (0.38, 0.95)
0 3.73 0 3.73
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mals. Indeed, these authors observed that returning ani-
mals to a normal, non-omega-3 PUFA deficient diet,
reversed some of the abnormalities they detected i.e. they
increased haloperidol-induced catalepsy. The discrepancy
between the two animal models may be due to hypersen-
sitivity of dopamine D2 receptors in the mesolimbic
dopamine system caused by decreased dopamine availa-
bility occurring subsequent to the omega-3 PUFA defi-
ciency [96]. Dopamine receptor sensitivity may then
overcome the effects of decreased dopamine abundance
resulting in increased locomotor activity. While this is a
reasonable explanation, the discrepancy between behav-
ioural and neurochemical results makes it impossible to
extend these animal model findings, with any certainty, to
human psychiatric illness. On the other hand, the results
reported by Levan and colleagues [96] would predict that
omega-3 PUFA should diminish symptoms of schizophre-
nia by means of reducing dopaminergic neurotransmis-
sion, and exacerbate attentional deficits by the same
mechanism. Since it is clear from the clinical trial data that
this does not happen, we are forced to conclude that the
model Levan and colleagues [96] used is not useful as a
means to understand the potential psychoactive effects of
omega-3 PUFA supplementation (although that does not
diminish the insight given into how omega-3 PUFA defi-
ciency in utero may play a role in the aetiology of mental
illness). It is, however, worth repeating, that an enhance-
ment of serotonergic, and possibly dopaminergic neuro-
transmission, by omega-3 PUFA is most consistent with
the results of the existing clinical trials of omega-3 PUFA
in mood disorders. Further progress in elucidating the
mechanism of omega-3 PUFA action is likely to come
from investigations using positron emission tomography
imaging which, with the selection of appropriate ligands,
can be used to assess dopaminergic and serotonergic func-
tion in the brain of patients [97].
At the biochemical level how might omega-3 PUFA defi-
ciency and supplementation affect the nervous system?
The conventional view [2] of omega-3 PUFA bioactivity is
that they act as negative regulators of the eicosanoid sign-
aling systems dependent upon the metabolism of the
omega-6 PUFA, AA e.g. the prostaglandin, leukotriene and
HETE pathways. Specifically, dietary supplementation
with omega-3 PUFA is thought to increase the abundance
of omega-3 PUFA in membrane phospholipids which can
then inhibit AA-dependent signalling either directly, by
replacing AA as the eicosanoid substrate of cyclooxygen-
ases and lipoxygenases, or indirectly by altering the
expression of proteins involved in the signalling cascade.
Given that the metabolites of AA have diverse effects
within the brain, including playing a role in dopaminergic
and serotonergic signaling systems, such an action by
omega-3 PUFA has been suggested to have important con-
sequences for brain physiology and behaviour [7]. For
example, agonists of dopamine D2 and D4 receptors acti-
vate AA-dependent signaling [98,99], while the produc-
tion of free AA and AA metabolites in response to
serotonin 5HT2 receptor occupancy is thought to play a
key role in the mechanism of SSRI action [100,101].
Although limited, such evidence suggests the use of AA-
dependent signaling by the neurotransmitter systems
known to be stimulated by existing treatments for mood,
anxiety and attentional disorders. Such data is not sup-
portive of a mechanism which postulates that omega-3
PUFA actually inhibits  this signaling pathway. Further-
more, although EPA is a minor brain fatty acid compared
to the abundant DHA [102], both omega-3 PUFA are
equally effective inhibitors of AA-derived eicosanoid syn-
thesis [103], a finding which is at odds with the observa-
tion that EPA may be more clinically efficacious in the
treatment of mood disorders.
Differential effects of EPA and DHA have, however, been
reported (for example see [104] and [105]). Of interest is
an in vitro observation obtained using the U937 monocyte
derived cell line which indicates that long term supple-
mentation with EPA can increase the stimulated release of
AA from membrane phospholipids, whereas DHA has no
effect [106]. This role of EPA was likely due to it inhibiting
the re-uptake of AA to reform an intact phospholipid, a
two enzyme metabolic pathway which acts to reverse the
hydrolysis of the AA-containing phospholipid by phos-
pholipase A2 [107]. Although the biochemical mecha-
nism is not fully understood, it is likely that EPA can
inhibit the expression and/or activity of the enzymes lys-
ophospholipid acyltransferase (LPAT) or fatty acid CoA
ligase (FACL), both of which are required for reuptake of
AA to occur [107]. Indeed, reduced activity of FACL
appears to enhance AA-dependent signaling reactions
since reduced reuptake will increase the supply of AA
available for eicosanoid synthesis [108]. Such a mecha-
nism is of interest given that it provides a means by which
AA-dependent signaling could be enhanced by its 20 car-
bon omega-3 PUFA counterpart, EPA, a characteristic
which, as we have argued, may enhance dopaminergic
and serotonergic neurotransmission.
Stimulation of AA-dependent signaling by EPA has also
been suggested by Horrobin and colleagues, but via a dif-
ferent mechanism: the ability of omega-3 PUFA to
increase the abundance of AA in membrane phospholip-
ids [109]. This again goes against conventional thinking
which maintains that omega-3 PUFA are antagonists of
AA-dependent processes. In what may prove to be an
important observation, these authors observed that feed-
ing rats a diet containing 0.01% or 0.1% EPA increased
levels of DHA, EPA and  AA, whereas a 1% EPA diet
increased DHA and EPA but decreased AA levels in eryth-
rocytes [109]. A similar relationship between EPA doseLipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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and AA levels was also noted in patients with schizophre-
nia who after receiving 1 g/day and 2 g/day EPA had ele-
vated erythrocyte AA levels, whereas 4 g/day EPA
decreased erythrocyte AA levels [109]. It is likely that a
reduction in AA abundance at higher EPA doses is due to
significant inhibition of AA uptake into the membrane,
possibly occurring via the inhibition of LPAT as described
earlier [106]. The mechanism by which low dose EPA
increases AA levels is unknown, but there is evidence that
EPA can elevate the activity of one of the other enzyme
involved in AA uptake, FACL [110]. As such, EPA and
potentially other omega-3 PUFA, appear to have two dis-
tinct cellular effects (and biochemical targets) with respect
to phospholipid metabolism: at low doses they may
enhance incorporation of both themselves and omega-6
PUFA into the membrane, but at higher doses they
decrease omega-6 incorporation. It is of interest to note
that of the two clinical trials examining the ability of
omega-3 PUFA to ameliorate attentional deficits which
reported a significant improvement in symptoms, in both
cases a combination of omega-3 and omega-6 PUFA were
administered [29,32]. It would also be of interest to inves-
tigate the possibility that omega-3 and omega-6 PUFA
may act in a synergistic (rather than antagonistic) manner
in future clinical trials. In addition, if enhancement of AA-
dependent signaling is the underlying mechanism of low
dose EPA action in mood disorders then it would be
expected that higher doses of EPA, which are associated
with decreased AA abundance [109], would have a lesser
antidepressant effect. Some evidence supports this
hypothesis given that 4 g/day or higher EPA is reported to
lack mood elevating activity in both major depressive dis-
order and bipolar disorder [66,81]. On the other hand,
high dose EPA was found to reduce the symptoms of
depression in another trial involving patients with bipolar
disorder [77], although in this trial EPA was co-adminis-
tered with DHA. To understand why adding DHA to EPA
may be more effective than EPA alone, especially at high
doses, it is worth remembering that EPA abundance in the
brain (approximately 0.2% of fatty acids) is much lower
than DHA (approximately 15% of fatty acids) [111,112].
Although supplementation with EPA does not change the
fact that DHA predominates in the brain, such supple-
mentation does have a much larger relative effect upon
EPA abundance compared to DHA abundance [111].
Thus, as EPA intake increases, the ratio of DHA to EPA in
the brain markedly falls. Since it is only recently that puri-
fied EPA has been available for human consumption, lit-
tle is known regarding the consequences for brain
function that administering high doses of EPA in the
absence of DHA may have. Although it is tempting to
attempt to extend the high purity, single compound norm
of the pharmaceutical industry to the field of nutrition,
the clinical trials data should alert us to the possibility that
administration of purified EPA alone may not in fact be
the most clinically effective formulation, and that the
addition of DHA, AA or other fatty acids could actually be
more beneficial for the patient. Such a hypothesis is testa-
ble using randomised clinical trials which compare the
relative efficacy of placebo, EPA, EPA/DHA and other
PUFA combinations.
Besides their role as modulators of AA-dependent signal-
ing, it is emerging that both EPA and DHA are precursors
of bioactive metabolites in their own right. For example,
EPA can be metabolised by cyclooxygenase to form the 3-
series prostaglandins [113]. Most recently, a new class of
compounds have been identified termed resolvins, with
EPA and DHA giving rise to the E- and D-series resolvins
respectively [114]. The resolvins appear to act via cell sur-
face receptors and are thought to have an important anti-
inflammatory role [114]. It has been confirmed that they
are formed in the nervous system but besides having a role
in reducing neuroinflammation their function remains
unknown [115,116]. Given that differences in function
between the EPA- and DHA-derived compounds have
already been identified [114], the possibility must be con-
sidered that one or more of these compounds may medi-
ate the psychoactive effects of EPA, and that drugs
designed to target their receptors may be therapeutically
useful as treatments for mental illness.
Conclusion
The available data are not supportive of omega-3 PUFA
being efficacious in the treatment of schizophrenia or bor-
derline personality disorders, while the investigation of
their use in anxiety disorders is at an early stage. Of all the
illnesses considered, the strongest evidence supports the
use of omega-3 PUFA in the treatment of mood disorders
with approximately 1 – 2 g/day of omega-3 PUFA appear-
ing to be effective. An ability of omega-3 PUFA to treat
attentional deficits is suggested by some trials although
strong evidence is lacking. Larger trials will hopefully be
conducted which allow more definitive statements to be
made regarding the efficacy of omega-3 PUFA in these dis-
orders over longer time periods, as well as determining the
most beneficial omega-3 PUFA formulation to use.
All of the clinical trials described in this review had one
conclusion in common – that omega-3 fatty acids had no
serious side effects (loose stool were sometimes, though
rarely, reported). These compounds, therefore, represent
an attractive and novel treatment modality. Although the
clinical trials varied in quality of design and tended to be
small in terms of participants, further investigation of the
use of omega-3 PUFA to treat at least some mental health
problems is warranted. Many recent trials have utilised
omega-3 formulations containing a high proportion of
EPA compared to other omega-3 types such as DHA. We
did find some evidence to support the use of such a high-Lipids in Health and Disease 2007, 6:21 http://www.lipidworld.com/content/6/1/21
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EPA formulation for treatment of depressive symptoms
although more study of the possibly differential efficacies
of omega-3 PUFA species is required. Moreover, it should
be noted that some evidence suggests that the use of for-
mulations containing only EPA and lacking any DHA may
actually be less effective than an EPA/DHA mixture, and
that combinatorial therapies which include mixtures of
both omega-3 and omega-6 PUFA should be considered
[81]. This may relate to the fact that the brain contains
predominantly DHA and the used of high levels of EPA
may have unforeseen negative consequences especially
when used over longer time periods.
Overall, based on the available evidence, it is not possible
to firmly recommend omega-3 PUFA as either sole or
adjunctive treatment for any of the mental illnesses con-
sidered. On the other hand, the research work done to
date is certainly exciting and offers a strong foundation on
which to base future clinical investigations.
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